Patient Assistance Program Shire Pharma Canada ULC (“Shire”) developed the VYVANSE Patient Assistance Program (the “Program”) for Canadian patients requiring support by covering for t

First Page		Document Content
Date: 2016-03-02 15:52:19 Amphetamine Substituted amphetamines TAAR1 agonists Medicine Nervous system Chemistry Lisdexamfetamine Prodrugs Shire Pharmacy UL		Patient Assistance Program Shire Pharma Canada ULC (“Shire”) developed the VYVANSE Patient Assistance Program (the “Program”) for Canadian patients requiring support by covering for t Add to Reading List Source URL: www.shirecanada.com Download Document from Source Website File Size: 200,45 KB Share Document on Facebook

	VYVANSE® [Vī’ - văns] MEDICATION GUIDE (lisdexamfetamine dimesylate) CII Capsules What is the most important information I should know about DocID: 1tcsc - View Document
	prilTreatments for Attention Deficit Hyperactivity Disorder in Adults FINAL PHARMACOEPIDEMIOLOGY REPORT DocID: 1pBj0 - View Document
	prilFINAL CONSOLIDATED REPORT DecemberDrugs Used in the Management of DocID: 1ou1z - View Document
	Microsoft Word - VYVANSE.Product Monographdoc DocID: 1m5V8 - View Document
	Patient Assistance Program Shire Pharma Canada ULC (“Shire”) developed the VYVANSE Patient Assistance Program (the “Program”) for Canadian patients requiring support by covering for t DocID: 1lpLs - View Document